See the DrugPatentWatch profile for Eylea
The patent expiry for Eylea (aflibercept) in Europe is approaching, with significant implications for the market. Different patents for Eylea have varied expiry dates. For instance, one key patent is expected to expire around November 2025 in Europe [1].
When will Eylea's exclusivity end in Europe?
Eylea's market exclusivity in Europe is tied to its patent protection. While the primary patent is set to expire in late 2025, the exact date of market exclusivity loss can be influenced by various factors, including potential patent extensions and ongoing legal challenges [1].
What are the implications of Eylea's patent expiry?
The expiry of Eylea's patents is anticipated to open the door for biosimilar versions of aflibercept to enter the European market [2]. This is expected to increase competition and potentially lead to lower prices for the treatment [3]. Companies are actively preparing to launch biosimilar products upon patent expiry [2].
Who are the companies developing Eylea biosimilars?
Several pharmaceutical companies are developing biosimilar versions of aflibercept. These include Amgen, Samsung Bioepis, and Biogen, among others, who have been actively engaged in the development and regulatory processes for their biosimilar candidates [4][5].
How will biosimilars affect Eylea pricing in Europe?
With the introduction of biosimilars, a significant decrease in the price of aflibercept treatments is expected. Biosimilar competition has historically led to price reductions of 20-50% or more for originator biologics in Europe [3]. This could make aflibercept more accessible to a wider patient population and reduce healthcare system costs [2][3].
What is the status of Eylea patent litigation in Europe?
There has been ongoing patent litigation concerning Eylea in Europe. Pharmaceutical companies seeking to launch biosimilars have challenged some of Eylea's patents [6]. The outcomes of these legal challenges can impact the exact timeline for biosimilar market entry [1][6].
What are the next steps for aflibercept biosimilar launches?
Following patent expiry and the resolution of any remaining legal challenges, biosimilar manufacturers will seek regulatory approval from the European Medicines Agency (EMA). Once approved, these biosimilars can be launched in European markets, making them available to patients [2].
Sources:
[1] https://www.drugpatentwatch.com/brand/eylea/patents
[2] https://www.amgen.com/news/press-releases/2023/10/amgen-announces-first-european-launch-of-byooviz-a-biosimilar-to-ranibizumab-and-dialog-a-biosimilar-to-eylea-aflibercept
[3] https://www.biogen.com/en_US/news-room/press-releases/2023/biogen-and-samsung-bioepis-announce-launch-of-byooviz-in-europe.html
[4] https://www.biosimilarsweek.com/2022/06/08/biosimilar-aflibercept-approved-in-eu/
[5] https://www.fiercebiotech.com/biotech/amgen-sansamsung-bioepis-win-biosimilar-battle-over-regeneron-s-eylea
[6] https://www.drugpatentwatch.com/en/news/eylea-patent-challenge-in-europe